Answers are grounded in this paper and cite their sources.
The exquisite target selectivity of monoclonal antibodies (mAbs) makes them an attractive starting point for developing radiopharmaceuticals for applications in diagnostic imaging and molecularly targeted radio(immuno)therapy (RIT). Combining mAbs with therapeutic β − -emitting radionuclides like 177 Lu, offers ways to overcome drug resistance but radiosynthesis of 177 Lu-mAbs poses numerous chemical challenges. Classic 177 Lu-radiochemistry relies on high temperatures and prolonged reaction times to achieve quantitative labelling but this is incompatible with the regular approach of radiolabelling antibodies that are pre-functionalised with a metal ion free chelate. Here, photochemistry was used to produce 177 Lu-onartuzumab in <30 min which was subjected to an array of chemical, in vitro stability, cellular and in vivo tests using mouse models of human gastric adenocarcinoma. Pilot imaging and biodistribution analyses confirmed the tumour targeting specificity of 177 Lu-onartuzumab. In RIT experiments, intravenous administration of low activities of [ 177 Lu]Lu- 1 -onartuzumab (3.764 ± 0.079 MBq) to mice bearing MKN-45 subcutaneous xenografts, followed by temporal γ-ray imaging and ultrasound analysis demonstrated pronounced therapeutic response versus chemical dose and tumour growth control groups. Collectively, the experimental data, alongside retrospective dosimetry modelling, validated the photoradiosynthesis approach for creating viable, molecularly targeted 177 Lu-mAbs in a flash.
No takes yet. Share an insight, caveat, or question.
Klingler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: